Interestingly, the metabolic phenotype of FH-deficient cells can more effectively resist conditions that are otherwise unfavorable for mitochondrial function, including hypoxia, suggesting that these changes might be selected during tumor progression. This evidence concerns the gene FH and neoplasm.